Premium
The outcomes of glucose abnormalities in pre‐diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy
Author(s) -
Huang JeeFu,
Yu MingLung,
Huang ChungFeng,
Juo SuhHang Hank,
Dai ChiaYen,
Hsieh MingYen,
Hou NeiJen,
Yeh MingLun,
Hsieh MengHsuan,
Yang JengFu,
Lin ZuYau,
Chen ShinnChern,
Shin ShyiJang,
Chuang WanLong
Publication year - 2012
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/j.1478-3231.2012.02771.x
Subject(s) - medicine , diabetes mellitus , gastroenterology , ribavirin , odds ratio , logistic regression , interleukin 28b , hepatitis c , risk factor , chronic hepatitis , endocrinology , immunology , virus
Background/Aims Pre‐diabetes is a risk factor for type 2 diabetes mellitus ( DM ) development. This study aimed to elucidate the impact of treatment response on sequential changes in glucose abnormalities in pre‐diabetic chronic hepatitis C ( CHC ) patients. Methods C hronic H epatitis C patients with a baseline haemoglobin A 1 C ( A 1 C ) range 5.7–6.4% who achieved 80/80/80 adherence were prospectively recruited. All patients received current peginterferon‐based recommendations. The primary outcome measurement was their A 1 C level at the end of follow‐up ( EOF ). The interaction between variants of the IL 28 B gene and outcomes of glucose metabolism was also measured. Results A total of 181 consecutive CHC patients were enrolled. The mean A 1 C at EOF was 5.82 ± 0.41%, which was significantly lower than the baseline level (5.93 ± 0.21%, P < 0.001). At EOF , 63 (34.8%) patients became normoglycaemic, whereas 10 (5.5%) patients developed DM . The sustained virological response ( SVR ) rates of 63 normoglycaemics, 108 pre‐diabetics and 10 diabetic patients at the EOF were 92.1%, 84.3% and 50% respectively (normoglycaemics vs. diabetics P = 0.003; pre‐diabetics vs. diabetics P = 0.02). Achievement of an SVR was the only predictive factor associated with normoglycaemia development at EOF by multivariate logistic regression analysis (Odds ratio = 2.6, P = 0.04). The prevalence of the interleukin 28 B rs8099917 TT variant in patients who developed DM (70.0%) at EOF tended to be lower than that in patients with pre‐diabetics (87.0%) or normoglycaemics (92.1%). Conclusion Successful eradication of HCV improves glucose abnormalities in pre‐diabetic CHC patients.